Effect of a Radiotherapeutic Megavoltage Beam on Ultrasound Contrast Agents

Gonzalo Collado-Lara; Sophie V. Heymans; Jeremy Godart; Emiliano D'Agostino; Jan D'hooge; Koen Van Den Abeele; Hendrik J. Vos; Nico de Jong

doi:10.1016/j.ultrasmedbio.2021.02.021

Effect of a Radiotherapeutic Megavoltage Beam on Ultrasound Contrast Agents

Gonzalo Collado-Lara^*, Sophie V. Heymans, Jeremy Godart, Emiliano D'Agostino, Jan D'hooge, Koen Van Den Abeele, Hendrik J. Vos, Nico de Jong

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Abstract

Collateral damage to healthy surrounding tissue during conventional radiotherapy increases when deviations from the treatment plan occur. Ultrasound contrast agents (UCAs) are a possible candidate for radiation dose monitoring. This study investigated the size distribution and acoustic response of two commercial formulations, SonoVue/Lumason and Definity/Luminity, as a function of dose on clinical megavoltage photon beam exposure (24 Gy). SonoVue samples exhibited a decrease in concentration of bubbles smaller than 7 µm, together with an increase in acoustic attenuation and a decrease in acoustic scattering. Definity samples did not exhibit a significant response to radiation, suggesting that the effect of megavoltage photons depends on the UCA formulation. For SonoVue, the influence of the megavoltage photon beam was especially apparent at the second harmonic frequency, and can be captured using pulse inversion and amplitude modulation (3.5-dB decrease for the maximum dose), which could eventually be used for dosimetry in a well-controlled environment.

Original language	English
Pages (from-to)	1857-1867
Number of pages	11
Journal	Ultrasound in Medicine and Biology
Volume	47
Issue number	7
DOIs	https://doi.org/10.1016/j.ultrasmedbio.2021.02.021
Publication status	Published - 1 Jul 2021

Bibliographical note

Funding Information:
The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (?AMPHORA?). The authors declare no conflict of interest.

Funding Information:
The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (“AMPHORA”).

Publisher Copyright:
© 2021 The Authors

Access to Document

10.1016/j.ultrasmedbio.2021.02.021

Cite this

@article{c600b9a979114484b6b8a9b00b92eb8f,

title = "Effect of a Radiotherapeutic Megavoltage Beam on Ultrasound Contrast Agents",

abstract = "Collateral damage to healthy surrounding tissue during conventional radiotherapy increases when deviations from the treatment plan occur. Ultrasound contrast agents (UCAs) are a possible candidate for radiation dose monitoring. This study investigated the size distribution and acoustic response of two commercial formulations, SonoVue/Lumason and Definity/Luminity, as a function of dose on clinical megavoltage photon beam exposure (24 Gy). SonoVue samples exhibited a decrease in concentration of bubbles smaller than 7 µm, together with an increase in acoustic attenuation and a decrease in acoustic scattering. Definity samples did not exhibit a significant response to radiation, suggesting that the effect of megavoltage photons depends on the UCA formulation. For SonoVue, the influence of the megavoltage photon beam was especially apparent at the second harmonic frequency, and can be captured using pulse inversion and amplitude modulation (3.5-dB decrease for the maximum dose), which could eventually be used for dosimetry in a well-controlled environment.",

author = "Gonzalo Collado-Lara and Heymans, {Sophie V.} and Jeremy Godart and Emiliano D'Agostino and Jan D'hooge and {Van Den Abeele}, Koen and Vos, {Hendrik J.} and {de Jong}, Nico",

note = "Funding Information: The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (?AMPHORA?). The authors declare no conflict of interest. Funding Information: The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (“AMPHORA”). Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.ultrasmedbio.2021.02.021",

language = "English",

volume = "47",

pages = "1857--1867",

journal = "Ultrasound in Medicine and Biology",

issn = "0301-5629",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Effect of a Radiotherapeutic Megavoltage Beam on Ultrasound Contrast Agents

AU - Collado-Lara, Gonzalo

AU - Heymans, Sophie V.

AU - Godart, Jeremy

AU - D'Agostino, Emiliano

AU - D'hooge, Jan

AU - Van Den Abeele, Koen

AU - Vos, Hendrik J.

AU - de Jong, Nico

N1 - Funding Information: The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (?AMPHORA?). The authors declare no conflict of interest. Funding Information: The authors acknowledge the team of the Cancer Research institute of Erasmus MC for their assistance during the calibration and performance of photon irradiation. The authors also thank Mark Borden for stimulating discussions, Robert Beurskens and Alex Brouwer for help on the setup and Klazina Kooiman, Joop Kouijzer, and Marcus Ingram for their support performing the experiments. This work was supported by the European Union's Horizon 2020 research and innovation program under Grant Agreement NO. 766456 (“AMPHORA”). Publisher Copyright: © 2021 The Authors

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Collateral damage to healthy surrounding tissue during conventional radiotherapy increases when deviations from the treatment plan occur. Ultrasound contrast agents (UCAs) are a possible candidate for radiation dose monitoring. This study investigated the size distribution and acoustic response of two commercial formulations, SonoVue/Lumason and Definity/Luminity, as a function of dose on clinical megavoltage photon beam exposure (24 Gy). SonoVue samples exhibited a decrease in concentration of bubbles smaller than 7 µm, together with an increase in acoustic attenuation and a decrease in acoustic scattering. Definity samples did not exhibit a significant response to radiation, suggesting that the effect of megavoltage photons depends on the UCA formulation. For SonoVue, the influence of the megavoltage photon beam was especially apparent at the second harmonic frequency, and can be captured using pulse inversion and amplitude modulation (3.5-dB decrease for the maximum dose), which could eventually be used for dosimetry in a well-controlled environment.

AB - Collateral damage to healthy surrounding tissue during conventional radiotherapy increases when deviations from the treatment plan occur. Ultrasound contrast agents (UCAs) are a possible candidate for radiation dose monitoring. This study investigated the size distribution and acoustic response of two commercial formulations, SonoVue/Lumason and Definity/Luminity, as a function of dose on clinical megavoltage photon beam exposure (24 Gy). SonoVue samples exhibited a decrease in concentration of bubbles smaller than 7 µm, together with an increase in acoustic attenuation and a decrease in acoustic scattering. Definity samples did not exhibit a significant response to radiation, suggesting that the effect of megavoltage photons depends on the UCA formulation. For SonoVue, the influence of the megavoltage photon beam was especially apparent at the second harmonic frequency, and can be captured using pulse inversion and amplitude modulation (3.5-dB decrease for the maximum dose), which could eventually be used for dosimetry in a well-controlled environment.

UR - http://www.scopus.com/inward/record.url?scp=85103480465&partnerID=8YFLogxK

U2 - 10.1016/j.ultrasmedbio.2021.02.021

DO - 10.1016/j.ultrasmedbio.2021.02.021

M3 - Article

C2 - 33810887

AN - SCOPUS:85103480465

SN - 0301-5629

VL - 47

SP - 1857

EP - 1867

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

IS - 7

ER -

Effect of a Radiotherapeutic Megavoltage Beam on Ultrasound Contrast Agents

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this